ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Prognostic significance of GLUT-1 in adenoid cystic carcinoma.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdenoid cystic carcinoma (ACC) is a common malignant tumor of the salivary glands. However, it lacks established prognostic markers. This study investigates the prognostic relevance of glucose transporter-1 (GLUT-1) in ACC.
methodsSeventy patients diagnosed with ACC were included in the study. Immunohistochemical analysis was performed to evaluate GLUT-1 expression levels by intensity, distribution, and scoring. These scores were correlated with clinicopathological parameters, overall survival (OS), and disease-free survival (DFS). The prognostic performance of GLUT-1 was assessed using ROC curve analysis and independent prognostic factors were identified through univariate and multivariate Cox regression models.
resultsThe GLUT-1 expression rate was 98.5%. Higher GLUT-1 scores were linked to solid histological subtype (p < 0.001), advanced T-stage (p < 0.001), perineural invasion (p < 0.001), lymph node metastasis (p = 0.009), and distant metastasis (p < 0.001). A GLUT-1 score > 5 accurately predicted mortality (AUC 0.921, 81.5% sensitivity, 95.3% specificity; p < 0.001), according to ROC analysis. Univariate analysis identified several risk factors for OS. In the multivariable Cox regression model, only a GLUT-1 score > 5 remained independently associated with a 14.7-fold increase in mortality risk (HR: 14.795; p = 0.003).
conclusionOur findings demonstrate that GLUT-1 expression is an independent prognostic marker for overall survival in ACC. Unlike traditional staging systems, the GLUT-1 score provides superior accuracy in risk stratification. Incorporating GLUT-1 scoring into routine pathological evaluation may facilitate the identification of high-risk patients and guide more personalized therapeutic strategies.
Indexed as
Identifiers
42543431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.